Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Q2 2025 value amounting to $26000.0.

  • Catalyst Pharmaceuticals' Capital Expenditures rose 16000.0% to $26000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $114000.0, marking a year-over-year decrease of 7967.91%. This contributed to the annual value of $556000.0 for FY2024, which is 14069.26% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Capital Expenditures stood at $26000.0 for Q2 2025, which was up 16000.0% from $88000.0 recorded in Q4 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Capital Expenditures peaked at $911000.0 during Q1 2021, and registered a low of $1000.0 during Q2 2021.
  • Over the past 4 years, Catalyst Pharmaceuticals' median Capital Expenditures value was $71000.0 (recorded in 2021), while the average stood at $152833.3.
  • Within the past 5 years, the most significant YoY rise in Catalyst Pharmaceuticals' Capital Expenditures was 30468.75% (2024), while the steepest drop was 537.63% (2024).
  • Over the past 4 years, Catalyst Pharmaceuticals' Capital Expenditures (Quarter) stood at $41000.0 in 2021, then soared by 126.83% to $93000.0 in 2023, then dropped by 5.38% to $88000.0 in 2024, then tumbled by 70.45% to $26000.0 in 2025.
  • Its Capital Expenditures stands at $26000.0 for Q2 2025, versus $88000.0 for Q4 2024 and $259000.0 for Q3 2024.